intractable partial epilepsy
Neurology · 2015–2016
2decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brivaracetam Intractable partial epileptic seizures in patients aged 16 years or older, either as add-on therapy in patients whose seizures have failed to be controlled by… | Jul 2016 | Not recommended | input received |
| lacosamide Continuation/maintenance treatment for intractable partial epileptic seizures in patients aged 16 years or older who have previously been treated with… | Mar 2015 | Recommended | no section in document |
What the PBS pays
$24M in government benefit over 2024–25, across 181,129 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lacosamide | $15M |
| brivaracetam | $8.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.